Dakota Wealth Management Increases Position in Boston Scientific Co. (NYSE:BSX)

Dakota Wealth Management boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 17.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,019 shares of the medical equipment provider’s stock after acquiring an additional 10,224 shares during the period. Dakota Wealth Management’s holdings in Boston Scientific were worth $6,075,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BSX. AE Wealth Management LLC lifted its holdings in shares of Boston Scientific by 18.9% in the 2nd quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock worth $1,252,000 after acquiring an additional 2,582 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Boston Scientific by 71.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 333,963 shares of the medical equipment provider’s stock valued at $25,718,000 after purchasing an additional 139,392 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Boston Scientific by 8.2% in the 2nd quarter. ProShare Advisors LLC now owns 216,039 shares of the medical equipment provider’s stock valued at $16,637,000 after buying an additional 16,430 shares during the last quarter. Epoch Investment Partners Inc. grew its position in shares of Boston Scientific by 10.8% in the 2nd quarter. Epoch Investment Partners Inc. now owns 8,616 shares of the medical equipment provider’s stock valued at $664,000 after buying an additional 840 shares during the last quarter. Finally, Gabelli Funds LLC grew its position in shares of Boston Scientific by 93.8% in the 2nd quarter. Gabelli Funds LLC now owns 183,526 shares of the medical equipment provider’s stock valued at $14,133,000 after buying an additional 88,826 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $100.90 on Wednesday. Boston Scientific Co. has a 52-week low of $59.85 and a 52-week high of $101.14. The firm has a fifty day moving average of $91.21 and a 200-day moving average of $84.76. The firm has a market capitalization of $148.71 billion, a P/E ratio of 83.39, a PEG ratio of 2.59 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business’s revenue was up 19.3% on a year-over-year basis. During the same period last year, the business earned $0.50 EPS. As a group, analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BSX shares. Mizuho increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Morgan Stanley increased their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Citigroup raised their price objective on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.